TickerTalks
Browse all tickers →
TickerTalks›$ENTX
ENENTX

Entera Bio Ltd.

$ENTX·$141M·Biotechnology·Healthcare
$2.89+0.7%YTD+46.4%1Y+46.7%
Mentions · last 7 days
2026-08-07: 8 posts2026-08-08: 0 posts2026-08-09: 0 posts2026-08-10: 8 posts2026-08-11: 4 posts2026-08-12: 4 posts2026-08-13: 1 posts25+4%
Price updated 22h ago·X counts updated 2d ago
ENENTX
$ENTXEntera Bio Ltd.
$2.89+0.70%25 posts+4%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $ENTX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventEvent coming upAI verdict · as of 2026-08-14

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Oral-peptide biotech with an FDA Phase 3 agreement on osteoporosis drug EB613 and a $275M oversubscribed PIPE that resets the runway — the setup is priced but the readout is far.

Entera Bio is pre-revenue with EPS -$0.05 to -$0.07 across the last four quarters (small burn) and the FDA has agreed on the Phase 3 design for EB613 (oral PTH(1-34)) in postmenopausal osteoporosis — this is the material catalyst that has priced the equity up 48% over 12 months.

  • Consensus FY26 revenue $54.6M / EPS -$0.34 (1 analyst) — the model reflects the PIPE closing rather than an operating revenue base; FY27 estimate revenue drops to essentially zero, which is a coverage/model artifact more than a business degradation.
  • X sentiment cites a $275M oversubscribed private placement that changes the development runway — that's a real de-risking event; but sentiment is also mixed, with short-timeframe traders flagging chop and one calling it 'an Israeli stock I should've left alone.'
  • Position 60% of 52-week range, +46% above 50-day and +66% above 200-day MA, beta 1.40 — the tape has already re-rated on the FDA news; incremental buying is paying for Phase 3 start execution.

Next dated event is 2026-11-13 earnings; the real event is Phase 3 initiation disclosure and any partnering announcement following the PIPE.

Agrees with X sentimentX reads the PIPE and FDA agreement as decisive de-risking events; the fundamental read backs the direction — the mixed retail-trader chop the crowd flags is real but not thesis-changing at this stage.

What to watch: Phase 3 EB613 initiation, any partnering disclosure post-PIPE, November 13 Q3 print for cash runway, and Canaccord growth-conference commentary.

On the calendar: 2026-11-13 — Q3 2026 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Mixed sentiment13 posts analyzed · as of 2026-08-04

Entera Bio chatter is short-timeframe trader flavor. Pre-market watchlists highlight ENTX for bullish pennants and demand-zone entries above VWAP, with some traders reporting green days after choppy sessions. The fundamental catalyst is a $275M oversubscribed private placement that changes the development runway. One trader takes a small loss and dismisses ENTX as an 'Israeli stock I should've left alone,' capturing a persistent skeptical thread inside the setup crowd.

Read the AI verdict + X sentiment for $ENTX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Oral drug delivery platform enabling large-molecule biologics as pills for hypoparathyroidism and osteoporosis.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $ENTX.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $ENTX

Partial — Oral drug delivery platform enabling large-molecule biologics as pills for hypoparathyroidism and osteoporosis; partial earnings exposure to biotechnology demand dynamics through its product portfolio.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+44.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-5.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-107%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-13.2%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-88.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 7, 2026$-0.14$-0.08-75.0%
Q1 2026May 8, 2026$-0.07$-0.08+12.5%
Q4 2025Mar 27, 2026$-0.07$-0.09+22.2%
Q3 2025Nov 14, 2025$-0.07$-0.09+22.2%
Next earningsFri, Nov 13·consensus EPS $-0.08

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0-100.0%——$-0.07$-3.1M
Q4 FY25$0-100.0%——$-0.07$-2.1M
Q3 FY25$0-100.0%——$-0.07$-2.8M
Q2 FY25$0-100.0%——$-0.06$-1.7M

Forward consensus

2-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$54.6M$54.6M – $54.6M-$0.34-$0.34 – -$0.341
FY27$6K$6K – $6K-$0.57-$0.57 – -$0.571

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.60%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+44.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+66.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 40.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.405-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyMar 9Geno J GermanoDirector20.0K sh$26KBuyMar 5Sean EllisDirector10.0K sh$12K
+ 12 other (12 awards) in window

See when $ENTX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDAug 78-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

Entera Bio Ltd. filed an 8-K reporting Q2 2026 financial results and a business update for the three months ended June 30, 2026. A press release was issued August 7, 2026 and furnished as Exhibit 99.1; no headline figures appear in the filing excerpt. Entera Bio is an Israeli clinical-stage company focused on oral delivery of large-molecule drugs, including an oral parathyroid hormone candidate for osteoporosis. This is a routine quarterly earnings and pipeline update disclosure.

SC 13DActivist position (5%+)Aug 4SC 13D
AI summary

A reporting person filed a Schedule 13D disclosing beneficial ownership of a disclosed percentage of ENTX's outstanding shares. A Schedule 13D signals a potentially activist or strategic stake above the 5% reporting threshold.

8-KMaterial agreementJul 288-K — Item 1.01: Material agreement · Item 3.02: Unregistered equity sale · Item 5.02: Officer or director change
AI summary

Entera Bio Ltd. (ENTX, Israel) entered a Securities Purchase Agreement with institutional and accredited investors including BVF Partners on July 26, 2026, raising approximately $275 million in a private placement by issuing 134,803,910 ordinary shares at $2.04/share (or pre-funded warrants in lieu); the transaction closed July 28, 2026 with 122,961,215 shares and 11,842,695 pre-funded warrants issued. Proceeds will fund Phase 3 registrational studies of EB613 for postmenopausal women and other pipeline activities. This is a highly dilutive capital raise — the share count more than doubles — but provides substantial runway for a late-stage biotech registrational program.

8-KOfficer or director changeJul 168-K — Item 5.02: Officer or director change · Item 5.03: Charter amendment · Item 5.07: Shareholder vote
AI summary

At Entera Bio's (ENTX) July 14, 2026 Annual Meeting, shareholders approved two structural changes: (1) a 2.5 million share increase to the 2018 Equity Incentive Plan, and (2) an amendment to the Articles of Association increasing authorized ordinary shares from 140.01 million to 350 million. Both amendments became effective immediately. The large authorized share increase — from 140M to 350M — is a material dilution-enabling change, likely needed to support future equity financings.

S-3Shelf registrationMay 8S-3
AI summary

State of Israel filed a S-3 shelf registration statement on 2026-05-08 covering securities. This registration enables future offerings at the company's discretion; it does not represent an immediate sale of securities. The shelf provides capital flexibility for potential future dilutive offerings, timing and size at management's discretion.

8-KPress release / Reg FDMay 88-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

Israel 001-38556 Not Applicable reported financial results for the period . Press release attached; detailed financials in the exhibit. Israel 001-38556 Not Applicable furnished a Reg FD disclosure covering: e 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financia.

8-KMaterial agreementApr 38-K — Item 1.01: Material agreement · Item 3.02: Unregistered equity sale
8-KPress release / Reg FDMar 278-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
+ 16 other (4 13Gs · 2 10-Qs · 2 proxys · 1 S-8) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreementmarketbeat.com·2d agoEntera Announces Second Quarter 2026 Financial Results and Business Updatesglobenewswire.com·8d agoEntera Bio Phase 2 Data Supporting EB613's (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meetingglobenewswire.com·11d agoEntera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conferenceglobenewswire.com·15d agoEntera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conferenceglobenewswire.com·15d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ABCL$CAPR$ALLO$NWBO$TENX$AURA$SION$IBRX
Voices on X · last 7 days

No standout posts about $ENTX on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport